ADRX: Andrx Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADRX: Andrx Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Axxel	4/7/2002 2:12:58 PM
	Read Replies (1) of 14

ADRX Andrx Group $ 49 techies are heading for the hills on this issue, but the break of $50 from the shelf of $50 is pretty severe in its own right-also there was some panic volume [we like that]. Andrx Corporation formulates and commercializes controlled-release oral pharmaceuticals using the Company's proprietary drug delivery technologies. For the 9 months ended 9/30/01, revenues rose 47% to $552.4M. Net income applicable to Andrx Group rose 40% to $68.6M. Revenues reflect sales of the Company's distribution of the bioequivalent version of Ventolin. Too newsy for us relative the FDA, but recent crash patterns push us to the attractive side. UPDATE 3.27.02: $39.10 we are not there yet. We would like to see some follow-through negative volume…so we will wait until we do.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next